Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Kura Oncology (NASDAQ:KURA) posted its quarterly earnings data on Tuesday. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.04, FiscalAI reports. Kura Oncology had a negative return on equity of 265.89% and a negative net margin of 369.26%. The firm had revenue of $22.84 million for the quarter, compared to the consensus estimate of $24.94 million.

Here are the key takeaways from Kura Oncology’s conference call:

• KOMZIFTI net product revenue rose 53% sequentially to $13.9 million, while new patient starts increased 30% and total prescriptions rose 65%. Kura said it retained a majority share of new menin-inhibitor starts and had expanded to 170 prescribing accounts.
• Kura reported eight ziftomenib abstracts at ASH, including first clinical data on combinations with FLT3 inhibitors. Its phase III frontline KOMET-017 program remains on track, with first topline results from the intensive-chemotherapy study expected in 2028.
• Kura said it aligned with the FDA on a single-arm study intended to support full approval of darlifarnib for HRAS-mutant salivary gland cancer. The company plans to begin the approximately 40-patient study in the first half of 2027, while acknowledging the path depends on clinical results.
• Kura ended September with $492 million in cash and investments and received $50 million in debt funding plus a $5 million equity investment under an Oberland agreement that provides up to $300 million. Management expects cash resources, financing proceeds, and anticipated partner payments to fund its current plan beyond the 2028 ziftomenib topline milestone.
• Collaboration revenue guidance for 2026 was revised to $40 million–$45 million; Kura maintained its $90 million–$110 million annual outlook for 2027 and 2028. The company noted that collaboration revenue reflects accounting recognition and not the timing of cash receipts.

Kura Oncology Stock Up 2.1%

Shares of KURA opened at $7.73 on Thursday. Kura Oncology has a 1 year low of $6.75 and a 1 year high of $13.90. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The stock has a 50 day simple moving average of $10.39 and a 200-day simple moving average of $9.78.

Insiders Place Their Bets

In other Kura Oncology news, insider Teresa Bair sold 8,442 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of $10.50, for a total transaction of $88,641.00. Following the completion of the transaction, the insider directly owned 187,002 shares in the company, valued at $1,963,521. This represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian T. Powl sold 15,430 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $165,872.50. Following the transaction, the insider owned 136,819 shares of the company’s stock, valued at $1,470,804.25. This represents a 10.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 153,881 shares of company stock worth $1,708,183 over the last quarter. Corporate insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on KURA. JPMorgan Chase & Co. started coverage on shares of Kura Oncology in a report on Thursday, October 1st. They set an “overweight” rating and a $30.00 price objective on the stock. UBS Group restated a “buy” rating on shares of Kura Oncology in a research note on Monday, October 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, October 14th. Raymond James Financial set a $24.00 price objective on Kura Oncology in a research report on Monday, August 24th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.35.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.